MX2021013942A - Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. - Google Patents

Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.

Info

Publication number
MX2021013942A
MX2021013942A MX2021013942A MX2021013942A MX2021013942A MX 2021013942 A MX2021013942 A MX 2021013942A MX 2021013942 A MX2021013942 A MX 2021013942A MX 2021013942 A MX2021013942 A MX 2021013942A MX 2021013942 A MX2021013942 A MX 2021013942A
Authority
MX
Mexico
Prior art keywords
methods
treating chronic
bruton
chronic spontaneous
spontaneous urticaria
Prior art date
Application number
MX2021013942A
Other languages
English (en)
Inventor
Martin Kaul
Thomas Severin
Bruno Bieth
Buck Stefan De
Souvik Bhattacharya
Maciej Cabanski
Bruno Cenni
Arvind Kinhikar
Andrijana Radivojevic
Julian Storim
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021013942A publication Critical patent/MX2021013942A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se relaciona con métodos para el tratamiento de la Urticaria Crónica Espontánea utilizando un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo. En la presente también se divulga un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo, para el tratamiento de pacientes con Urticaria Crónica Espontánea, así como también medicamentos, regímenes de dosificación, formulaciones farmacéuticas, formas de dosificación, y kits para utilizar en los usos y métodos divulgados.
MX2021013942A 2019-05-23 2020-05-20 Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. MX2021013942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021013942A true MX2021013942A (es) 2022-01-04

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013942A MX2021013942A (es) 2019-05-23 2020-05-20 Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.

Country Status (13)

Country Link
US (1) US20220184074A1 (es)
EP (1) EP3972604A1 (es)
JP (1) JP2022533981A (es)
KR (1) KR20220012281A (es)
CN (1) CN113795255A (es)
AU (1) AU2020280272A1 (es)
BR (1) BR112021022602A2 (es)
CA (1) CA3138081A1 (es)
CL (1) CL2021003032A1 (es)
IL (1) IL286983A (es)
MX (1) MX2021013942A (es)
TW (1) TW202110450A (es)
WO (1) WO2020234782A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240055038A (ko) 2021-09-03 2024-04-26 노파르티스 아게 다발성 경화증 치료를 위한 lou064
WO2023111802A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives

Also Published As

Publication number Publication date
KR20220012281A (ko) 2022-02-03
WO2020234782A1 (en) 2020-11-26
JP2022533981A (ja) 2022-07-27
IL286983A (en) 2021-12-01
AU2020280272A1 (en) 2021-11-18
EP3972604A1 (en) 2022-03-30
BR112021022602A2 (pt) 2022-01-04
CL2021003032A1 (es) 2022-09-09
CN113795255A (zh) 2021-12-14
US20220184074A1 (en) 2022-06-16
CA3138081A1 (en) 2020-11-26
TW202110450A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
CR20230310A (es) Inhibidores de prmt5
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
GB0112348D0 (en) Compounds
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MY196869A (en) Cancer treatment combinations
SE0202429D0 (sv) Novel Compounds
PH12016502353A1 (en) Pharmaceutical composition
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
PH12021551371A1 (en) Pharmaceutical composition for the treatment of pulmonary arterial hypertension
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2022016341A (es) Formas farmaceuticas de maleato de acalabrutinib.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy